Johnson & Johnson Q4 Profit Decreases
· 20h
Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
· 21h
Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing
· 1d
Johnson & Johnson Q4 Profit Decreases, But Beats Estimates
Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The
· 5h · on MSN
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment
· 20h
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,
· 21h
FDA approves first-of-its-kind nasal spray for severe depression
Some results have been hidden because they may be inaccessible to you
Show inaccessible results